<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991638</url>
  </required_header>
  <id_info>
    <org_study_id>HKUBTK01</org_study_id>
    <nct_id>NCT02991638</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers</brief_title>
  <official_title>Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other&#xD;
      indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B&#xD;
      virus carriers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibrutinib is a selective oral Burton tyrosine kinase inhibitor. Through interfering with the&#xD;
      downstream pathways of B-cell receptor signaling, it inhibits proliferation and induces&#xD;
      apoptosis in many B-cell lymphoid malignancies. The clinical benefit of ibrutinib has been&#xD;
      demonstrated in patients with relapsed/refractory chronic lymphocytic leukaemia, mantle cell&#xD;
      lymphoma, small lymphocytic lymphoma, and other indolent B-cell non-Hodgkin lymphomas.&#xD;
&#xD;
      The pivotal trials of ibrutinib excluded HBsAg+ patients. Therefore, the effects of ibrutinib&#xD;
      on HBsAg+ and anti-HBc+ patients remain entirely undefined. In view of the B-cell signaling&#xD;
      inhibitory activity of ibrutinib, which might be more potent than rituximab in suppressing&#xD;
      B-cells, HBV reactivation in patients exposed previously to HBV infection, including chronic&#xD;
      HBV carriers and occult HBV carriers, could be a major clinical problem.&#xD;
&#xD;
      To enable ibrutinib to be prescribed in Asia and other regions of the world where HBV is&#xD;
      endemic, evidence-based recommendations on prevention of HBV reactivation in at-risk&#xD;
      populations, including chronic HBV carriers (HBsAg+), and occult HBV carriers (HBsAg- but&#xD;
      anti-HBc+), are urgently needed.&#xD;
&#xD;
      The following treatment regimens will be adopted. Relapsed / refractory chronic lymphocytic&#xD;
      leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily.&#xD;
&#xD;
      Relapsed / refractory mantle cell lymphoma: 560 mg daily. Relapsed / refractory indolent&#xD;
      B-cell non-Hodgkin lymphoma: 560 mg daily. Treatment is continued until disease progression.&#xD;
&#xD;
      A total of 62 patients will be recruited, including 16 HBsAg+ patients, and 46 occult HBV&#xD;
      carriers&#xD;
&#xD;
      Sample size calculation of occult HBV carriers For occult HBV carriers, the sample size is&#xD;
      calculated according to the following information, based on our previous observations (as&#xD;
      detailed in reference 3). The HBV reactivation rate in HBsAg-, anti-HBc+, anti-HBs+ patients&#xD;
      is hypothesized to be 34%, which may increase to 68% in HBsAg-, anti-HBc+, but anti-HBs-&#xD;
      patients [3]. Assuming a power of 80% and an alpha-risk of 0.1, together with the ratio of&#xD;
      anti-HBs+ : anti-HBs- patients to be 2:1, we expect to recruit 42 HBsAg-, anti-HBc+ patients.&#xD;
      With a dropout rate of 10%, the total number of patients to be recruited in this group will&#xD;
      be 46.&#xD;
&#xD;
      Sample size calculation of HBsAg+ patients For HBsAg+ patients, the sample size is calculated&#xD;
      according to the following information, based on our previous observations (as detailed in&#xD;
      reference 3). The ratio of occult carriers (HBsAg-, anti-HBc+) : HBsAg+ patients is about 3:&#xD;
      1.3 Hence, the total number of HBsAg+ to be recruited will be 14 (42 divided by 3). With a&#xD;
      drop-out rate of 10%, the total number of patients to be recruited in this group will be 16.&#xD;
&#xD;
      Approximate breakdown of number of patients in each category to be recruited Based on our&#xD;
      previous observations on the proportions of low-grade B-cell lymphoid malignancies,8 an&#xD;
      approximate breakdown of number of patients is as follows: follicular lymphoma (N=32),&#xD;
      chronic lymphocytic leukemia/small lymphocytic lymphoma (N=11), marginal zone B-cell lymphoma&#xD;
      (N=11), mantle cell lymphoma (N=5), and Waldenstrom macroglobulinemia (N=5).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>proportion of patients achieving CR or partial remission (PR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of HBV Reactivation while on Ibrutinib therapy</measure>
    <time_frame>two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events and severe adverse events</measure>
    <time_frame>two year</time_frame>
    <description>Incidence of AE and SAE by severity grading as assessed according to CTCAE v4.03</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Indolent B-cell Lymphomas</condition>
  <condition>Chronic Hepatitis B</condition>
  <condition>Lymphoma, Small Lymphocytic</condition>
  <condition>Mantle-Cell Lymphoma</condition>
  <condition>Waldenstrom's Macroglobulinaemia</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression</description>
    <arm_group_label>Ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients between age of 18 - 80 years&#xD;
&#xD;
          2. Patients with indolent B-cell lymphoproliferative neoplasms that have relapsed or are&#xD;
             refractory after at least one standard line of therapy that contains rituximab&#xD;
&#xD;
          3. Pathologically proven B-cell lymphoproliferative neoplasms including chronic&#xD;
             lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal-zone&#xD;
             B-cell lymphoma, and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma).&#xD;
&#xD;
          4. Pathologically proven follicular lymphoma, with relapse or disease progression &gt; 12&#xD;
             months after previous rituximab therapy.&#xD;
&#xD;
          5. Chronic HBV carriers (HBsAg+)&#xD;
&#xD;
          6. Occult HBV carriers (HBsAg-, anti-HBc+ and HBV DNA-)&#xD;
&#xD;
          7. Haematology values within the following limits:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC)1000/mm3 independent of growth factor support&#xD;
&#xD;
               2. Platelets 100,000/mm3, or 50,000/mm3 if bone marrow is involved, and independent&#xD;
                  of transfusion support in either situation&#xD;
&#xD;
          8. Biochemical values within the following limits:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or&#xD;
                  of non-hepatic origin&#xD;
&#xD;
               3. Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft&#xD;
                  Gault) ≥ 40 mL/min/1.73m2&#xD;
&#xD;
          9. Competent to give an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant chronic liver diseases not related to HBV&#xD;
&#xD;
          2. Known history of drug-induced liver injury, chronic active hepatitis C infection,&#xD;
             alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis,&#xD;
             on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver&#xD;
             and portal hypertension&#xD;
&#xD;
          3. Known history of drug induced pneumonitis&#xD;
&#xD;
          4. Known history of inflammatory bowel disease&#xD;
&#xD;
          5. Woman who are pregnant or breast-feeding&#xD;
&#xD;
          6. Patients who do not consent to the use of effective contraception during the study&#xD;
&#xD;
          7. Active infections.&#xD;
&#xD;
          8. Evidence of ongoing active HBV hepatitis (ALT and/or AST &gt; 2x upper limit of normal,&#xD;
             and detectable HBV DNA)&#xD;
&#xD;
          9. Patients known to have histological transformation of CLL to an aggressive lymphoma&#xD;
&#xD;
         10. Vaccinated with live, attenuated vaccines within 4 weeks of enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yok Lam Kwong, MD(HK),</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>King Hei Lu, MMedSc</last_name>
    <phone>852-22554361</phone>
    <phone_ext>1654</phone_ext>
    <email>khlu@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zoe Chan, BNs</last_name>
    <phone>852-22551654</phone>
    <email>zoechan1@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>King Hei Lu, MMedSc</last_name>
      <phone>852-22554361</phone>
      <phone_ext>1654</phone_ext>
      <email>khlu@hku.hk</email>
    </contact>
    <contact_backup>
      <last_name>Zoe Chan, BNs</last_name>
      <phone>852-22551654</phone>
      <email>zoechan1@hku.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Yok Lam Kwong, MD(HK)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Tse, MBBS(HK), PhD(Cantab)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Yok-lam Kwong</investigator_full_name>
    <investigator_title>Chair Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

